Solara Active Pharma Sciences Ltd
Q4 FY26 Earnings Call Analysis
Pharmaceuticals & Biotechnology
fundraise: No informationcapex: Yesrevenue: Category 3margin: Category 3orderbook: No information
💰fundraise
Any current/future new fundraising through debt or equity?
No information is provided regarding the same in the latest conference call.
🏗️capex
Any current/future capex/capital investment/strategic investment?
No information is provided regarding the same in the latest conference call.
📊revenue
Future growth expectations in sales/revenue/volumes?
No information is provided regarding the same in the latest conference call.
📈margin
Future growth expectations in earnings/operating earnings/profits/EPS?
No information is provided regarding the same in the latest conference call.
📋orderbook
Current/ Expected Orderbook/ Pending Orders?
- The transcript does not explicitly mention the current or expected order book or pending orders for Solara Active Pharma Sciences Limited.
- The company highlighted six key product approvals and 11 market extensions in Q3, focusing on portfolio maximization, new geographies, and new customers, which implies future order inflows.
- The CRAMS business order pipeline seems positive with plans to grow revenue to approximately Rs. 500 crores in 3-4 years.
- The Vizag CRAMS facility retrofit and investments suggest ongoing and future projects.
- The company is focusing on cost improvements and margin expansion, implying they expect steady demand.
- Overall, no quantitative order book details provided, but ongoing approvals and investments indicate a growing order pipeline.